Loading clinical trials...
Loading clinical trials...
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of M4344 (Formerly VX-803) as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Conditions
Interventions
M4344 10 mg BIW
M4344 20 mg BIW
+15 more
Locations
16
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Washington University in St. Louis
St Louis, Missouri, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York, United States
Tennessee Oncology
Nashville, Tennessee, United States
Start Date
January 26, 2015
Primary Completion Date
June 16, 2021
Completion Date
September 24, 2021
Last Updated
March 16, 2023
NCT05720117
NCT06898450
NCT06658951
NCT05101070
NCT05098132
NCT05223608
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions